Dusheiko GM - Search Results

1

Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.

Flamm SL, Muir AJ, Fried MW, Reddy KR, Nelson DR, Bzowej NH, Sullivan JC, Bengtsson L, DeMasi R, Wright CI, Kieffer TL, George S, Adda N, Dusheiko GM. Flamm SL, et al. Among authors: dusheiko gm. J Clin Gastroenterol. 2015 Apr;49(4):336-44. doi: 10.1097/MCG.0000000000000150. J Clin Gastroenterol. 2015. PMID: 24828357

2

Selective regional chemotherapy of unresectable hepatic tumours using lipiodol.

Novell JR, Dusheiko G, Markham NI, Reddy K, Dick R, Hobbs KE. Novell JR, et al. HPB Surg. 1991 Sep;4(3):223-34; discussion 234-6. doi: 10.1155/1991/34537. HPB Surg. 1991. PMID: 1657118 Free PMC article.

3

Evolution of hepatitis B virus during primary infection in humans: transient generation of cytotoxic T-cell mutants.

Whalley SA, Brown D, Webster GJ, Jacobs R, Reignat S, Bertoletti A, Teo CG, Emery V, Dusheiko GM. Whalley SA, et al. Among authors: dusheiko gm. Gastroenterology. 2004 Oct;127(4):1131-8. doi: 10.1053/j.gastro.2004.07.004. Gastroenterology. 2004. PMID: 15480991

4

Ribavirin considerations in treatment optimization.

Dusheiko G, Nelson D, Reddy KR. Dusheiko G, et al. Antivir Ther. 2008;13 Suppl 1:23-30. Antivir Ther. 2008. PMID: 18432160 Review.

5

Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha2b: a report of two cases.

Kajihara M, Montagnese S, Khanna P, Amodio P, Schapira AH, Dusheiko GM, Morgan MY. Kajihara M, et al. Among authors: dusheiko gm. Eur J Gastroenterol Hepatol. 2010 May;22(5):628-31. doi: 10.1097/MEG.0b013e32833383e3. Eur J Gastroenterol Hepatol. 2010. PMID: 20075741

6

Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.

Burney T, Dusheiko G. Burney T, et al. Expert Rev Anti Infect Ther. 2011 Feb;9(2):151-60. doi: 10.1586/eri.10.153. Epub 2010 Dec 14. Expert Rev Anti Infect Ther. 2011. PMID: 21143041 Review.

7

Treatment decisions and contemporary versus pending treatments for hepatitis C.

Trembling PM, Tanwar S, Rosenberg WM, Dusheiko GM. Trembling PM, et al. Among authors: dusheiko gm. Nat Rev Gastroenterol Hepatol. 2013 Dec;10(12):713-28. doi: 10.1038/nrgastro.2013.163. Epub 2013 Sep 10. Nat Rev Gastroenterol Hepatol. 2013. PMID: 24019151 Review.

8

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.

Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. Cure S, et al. J Med Econ. 2014 Jan;17(1):77-87. doi: 10.3111/13696998.2013.844159. Epub 2013 Nov 21. J Med Econ. 2014. PMID: 24032626 Free article.

9

Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.

Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D. Afdhal NH, et al. Among authors: dusheiko gm. Gastroenterology. 2014 Feb;146(2):442-52.e1. doi: 10.1053/j.gastro.2013.10.012. Epub 2013 Oct 12. Gastroenterology. 2014. PMID: 24126097 Clinical Trial.

10

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.

Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. Cure S, et al. J Med Econ. 2014 Jan;17(1):65-76. doi: 10.3111/13696998.2013.860033. Epub 2013 Nov 18. J Med Econ. 2014. PMID: 24160335 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

167 results

Search Page